

12 Oct 2020 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

Join us for an audio roundup of major events in the international biopharma industry over the past week, as covered by *Scrip's* global team.

Take a brief audio tour round *Scrip's* Five Must-Know Things, this time for the business week ended 9 October 2020.

In this edition, we look at the impact on clinical trials of President Trump's treatment for COVID-19, a major acquisition by BMS, a planned EUA for Lilly's covid antibody therapy, change at the top at Merck Research Labs, and a forward view on major new drug approvals expected in the coming months.

This and other Informa Pharma Intelligence podcasts are also now voice-accessible via Alexa smart speakers and the Alexa app, once set up as a skill. Just say "Alexa, Open Informa - Pharma Intelligence" and then ask for a specific podcast or topic.

Stories mentioned in this episode:

(Also see "[*Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire*](#)" - Scrip, 4 Oct, 2020.)

(Also see "[*BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten*](#)" - Scrip, 5 Oct, 2020.)

(Also see "[*Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data*](#)" - Scrip, 7 Oct, 2020.)

(Also see "[*Merck's Perlmutter Is Retiring, Handing Over Keytruda To Li*](#)" - Scrip, 2 Oct, 2020.)

(Also see "[*12 Approvals To Look Out For In Q4*](#)" - Scrip, 7 Oct, 2020.)

[Click here to explore this interactive content online](#) 